Metsera (NASDAQ:MTSR) Shares Gap Up - Here's Why

Metsera, Inc. (NASDAQ:MTSR - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $21.18, but opened at $22.01. Metsera shares last traded at $19.15, with a volume of 122,076 shares.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Guggenheim started coverage on Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price objective on the stock. Evercore ISI initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating for the company. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating on the stock.

Metsera Stock Up 1.7 %

The business's 50-day moving average price is $23.40.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Metsera stock. Bank of New York Mellon Corp bought a new position in Metsera, Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 32,494 shares of the company's stock, valued at approximately $884,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.